Comparing the current results to its competitors, Surrozen Inc reported Revenue increase in the 2 quarter 2026 by 408.65 % year on year. The sales growth was above Surrozen Inc 's competitors' average revenue growth of 39.94 %, achieved in the same quarter.
Surrozen Inc 's Comment on Competition and Industry Peers
Surrozen operates in the pharmaceutical and biotechnology industries, which are characterized by rapid technological advancements and intense competition. The company faces competition from multinational pharmaceutical companies, established biotechnology firms, specialty pharmaceutical companies, universities, academic institutions, government agencies, and other research organizations. In the treatment of retinal diseases, Surrozen competes with large pharmaceutical and biotechnology companies that have commercially approved products. Notable competitors with approved treatments for wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion include Roche, Regeneron, and Novartis. These competitors' drugs are well established and widely accepted by physicians, patients, and third-party payors.
June 10, 2024
At the prestigious 2024 European Association for the Study of the Liver (EASL) conference held in Milan, Surrozen Inc., a front-runner in biopharmaceutical innovation, presented groundbreaking preliminary results from its Phase 1a clinical study of SZN-043. This investigational drug is specifically aimed at addressing unmet medical needs in patients with liver cirrhosis, a condition characterized by severe liver damage and impaired liver function.SZN-043 is a novel therapeutic agent designed to modulate Wnt signaling pathways, which play a crucial role in tissue repair and regeneration. The results emanating from this early-phase trial offer a glimpse into the drug’s potential, both in terms of safety and ...
April 3, 2024
Surrozen Publishes Study in nRespiratory Researchn Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary FibrosisPulmonary fibrosis, a progressive and debilitating lung disease characterized by the formation of scar tissue in the lungs, affects millions of people worldwide. Despite years of research, effective treatments for this condition have remained elusive. However, a recent study published by the renowned biotech company, Surrozen, in the esteemed journal nRespiratory Researchn, has shed light on a potential breakthrough in the treatment of pulmonary fibrosis.The study focused on the use of a novel therapeutic agent termed a Wnt mimetic antibody. This innovative antibody works by mi...
January 18, 2024
In a recent corporate update, biopharmaceutical company Surrozen announced a strategic prioritization of its clinical programs to concentrate on the development of SZN-043, a potential treatment for Alcohol-Associated Hepatitis (AAH). This decision marks a significant shift in Surrozen s research focus and holds considerable promise for addressing a pressing unmet medical need. This article aims to outline the pertinent facts gleaned from the announcement, shedding light on Surrozen s latest endeavors.Research Prioritization:Surrozen s recently announced strategic prioritization of clinical programs reflects a conscious choice to streamline efforts toward developing SZN-043 for AAH treatment. This disease, c...
Biocryst Pharmaceuticals Inc is a biotechnology company that focuses on the discovery and development of small-molecule drugs for rare diseases. They leverage their expertise in protein crystallography and drug design to create innovative therapies targeting specific proteins associated with certain diseases. Biocryst aims to bring these treatments to market by partnering with pharmaceutical companies or pursuing commercialization independently.
Arrowhead Pharmaceuticals Inc is a biopharmaceutical company that primarily focuses on developing RNA interference (RNAi) therapeutics to treat a wide range of diseases. Their business model revolves around discovering and optimizing RNAi-based drug candidates, conducting preclinical and clinical studies for regulatory approval, and ultimately licensing or partnering with larger pharmaceutical companies for commercialization. By leveraging RNAi technology, Arrowhead aims to address unmet medical needs and provide innovative treatments for patients.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Sources:
Surrozen Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Surrozen Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
